About Dren Bio
Dren Bio is a company based in San Carlos (United States) founded in 2019 by John Wesley and Nenad Tomasevic. Dren Bio has raised $131 million across 3 funding rounds from investors including Pfizer, ARE and Revelation Partners. Dren Bio operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter San Carlos, United States
- Founders John Wesley, Nenad Tomasevic
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$131 M (USD)
in 3 rounds
-
Latest Funding Round
$65 M (USD), Series B
Mar 28, 2022
-
Investors
Pfizer
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Dren Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Dren Bio
Dren Bio has successfully raised a total of $131M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $65 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dren Bio
Dren Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, ARE and Revelation Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
A biotechnology venture capital firm investing in innovative science.
|
Locked | Locked | Locked |
Investor details for Dren Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dren Bio
Investment portfolio details for Dren Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dren Bio
Detailed financials for Dren Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dren Bio Comparisons
Peer comparison for Dren Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dren Bio
Dren Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Dren Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dren Bio
Complete news archive for Dren Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dren Bio
Dren Bio was founded in 2019.
Dren Bio is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Nenad Tomasevic is the current CEO of Dren Bio. They have also founded this company.
Dren Bio is a funded company, having raised a total of $131M across 3 funding rounds to date.
Dren Bio was founded in 2019 and is headquartered in San Carlos, United States. Antibodies are developed for treating cancer, autoimmune conditions, and other serious diseases within the biotechnology sector. Operations focus on candidates like DR-01, a nonfucosylated antibody for hematologic malignancies, and DR-0201, a targeted myeloid engager using a phagocytosis platform for B cell malignancies.
Dren Bio's top competitors include Moderna, argenx and Forge Biologics.
Dren Bio has 11 investors. Key investors include Pfizer, ARE, Revelation Partners, HBM Healthcare Investments, and ArrowMark Partners.